Jenavalve Technology, Inc.

Jenavalve Technology, Inc. company information, Employees & Contact Information

JenaValve is a medical device company developing the first transcatheter heart valve technology that is uniquely designed for the minimally invasive treatment of aortic regurgitation (AR). The JenaValve Trilogy Heart Valve System is the first and only device currently approved in the EU for the treatment of severe, symptomatic aortic regurgitation in patients that are deemed high-risk for surgical aortic valve replacement. The Trilogy System is also CE-Mark approved for treatment of severe, symptomatic aortic stenosis. In the US, JenaValve has completed enrollment of the ALIGN-AR IDE Clinical Trial which will support a future PMA submission. If approved, the Trilogy System would become the first and only TAVR system in the US indicated for the treatment of symptomatic, severe AR. JenaValve is headquartered in Irvine, California with offices in Leeds, U.K. and Munich, Germany.

Company Details

Employees
171
Founded
-
Address
4 Cromwell,
Phone
(895) 527-9080
Email
in****@****alve.de
Industry
Medical Equipment Manufacturing
NAICS
Medical Equipment and Supplies Manufacturing
Surgical and Medical Instrument Manufacturing
Surgical Appliance and Supplies Manufacturing
Dental Equipment and Supplies Manufacturing
Ophthalmic Goods Manufacturing
Dental Laboratories
Keywords
Technician jobs.
HQ
Irvine, CA
Looking for a particular Jenavalve Technology, Inc. employee's phone or email?

Jenavalve Technology, Inc. Questions

News

JenaValve Announces Late-Breaking Data from the ALIGN-AR Pivotal Trial - GlobeNewswire

JenaValve Announces Late-Breaking Data from the ALIGN-AR Pivotal Trial GlobeNewswire

FTC challenge to Edwards JenaValve acquisition could delay FDA approval - Cardiovascular Business

FTC challenge to Edwards JenaValve acquisition could delay FDA approval Cardiovascular Business

FTC aims to stop Edwards' acquisition of JenaValve - Fierce Biotech

FTC aims to stop Edwards' acquisition of JenaValve Fierce Biotech

FTC moves to block Edwards’ JenaValve acquisition - MedTech Dive

FTC moves to block Edwards’ JenaValve acquisition MedTech Dive

FTC seeks to block Edwards Lifesciences' acquisition of JenaValve - Reuters

FTC seeks to block Edwards Lifesciences' acquisition of JenaValve Reuters

JenaValve enrolls first patient in TAVR for AR study - MassDevice

JenaValve enrolls first patient in TAVR for AR study MassDevice

JenaValve Responds to FTC’s Action Against Proposed Edwards Lifesciences Acquisition - The Manila Times

JenaValve Responds to FTC’s Action Against Proposed Edwards Lifesciences Acquisition The Manila Times

FTC moves to block Edwards Lifesciences’ JenaValve acquisition - MassDevice

FTC moves to block Edwards Lifesciences’ JenaValve acquisition MassDevice

JenaValve Announces ALIGN-AR Pivotal Data to be Presented During the Late-Breaking Clinical Trial Sessions at TCT 2023 - Diagnostic and Interventional Cardiology

JenaValve Announces ALIGN-AR Pivotal Data to be Presented During the Late-Breaking Clinical Trial Sessions at TCT 2023 Diagnostic and Interventional Cardiology

FTC to block Edwards Lifesciences’ acquisition of JenaValve due to competitive concerns - Medical Device Network

FTC to block Edwards Lifesciences’ acquisition of JenaValve due to competitive concerns Medical Device Network

FTC Challenges Edwards's Proposed Acquisition of JenaValve - Medical Device and Diagnostic industry

FTC Challenges Edwards's Proposed Acquisition of JenaValve Medical Device and Diagnostic industry

FTC moves to block Edwards Lifesciences’ acquisition of JenaValve - Medical Economics

FTC moves to block Edwards Lifesciences’ acquisition of JenaValve Medical Economics

US FTC moves to thwart Edwards’ acquisition of Jenavalve - BioWorld MedTech

US FTC moves to thwart Edwards’ acquisition of Jenavalve BioWorld MedTech

Edwards Lifesciences Comments on FTC’s Action to Block Proposed Acquisition of JenaValve - Business Wire

Edwards Lifesciences Comments on FTC’s Action to Block Proposed Acquisition of JenaValve Business Wire

JenaValve data backs TAVR system for treating aortic regurgitation - MassDevice

JenaValve data backs TAVR system for treating aortic regurgitation MassDevice

Edwards Lifesciences inks $1.6B in acquisition deals for JenaValve, Endotronix - Fierce Biotech

Edwards Lifesciences inks $1.6B in acquisition deals for JenaValve, Endotronix Fierce Biotech

Chinese made version of JenaValve TAVR device implanted in first patient - Cardiovascular Business

Chinese made version of JenaValve TAVR device implanted in first patient Cardiovascular Business

Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix - Business Wire

Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix Business Wire

Analysts expect JenaValve TAVR approval for aortic regurgitation in 2025 - MassDevice

Analysts expect JenaValve TAVR approval for aortic regurgitation in 2025 MassDevice

JenaValve applauds new European TAVI guidelines - MassDevice

JenaValve applauds new European TAVI guidelines MassDevice

FTC Files Lawsuit to Block Edwards Lifesciences’ Purchase of JenaValve Technology - The Wall Street Journal

FTC Files Lawsuit to Block Edwards Lifesciences’ Purchase of JenaValve Technology The Wall Street Journal

Novartis to Acquire Avidity Biosciences in $12 Billion Deal to Expand Neuroscience Portfolio - PYMNTS.com

Novartis to Acquire Avidity Biosciences in $12 Billion Deal to Expand Neuroscience Portfolio PYMNTS.com

JenaValve to begin Trilogy heart valve trial - MassDevice

JenaValve to begin Trilogy heart valve trial MassDevice

Edwards Lifesciences agrees to acquire JenaValve, Endotronix for $1.2B - Cardiovascular Business

Edwards Lifesciences agrees to acquire JenaValve, Endotronix for $1.2B Cardiovascular Business

Edwards Lifesciences' deal with JenaValve would limit device access, US FTC says - MLex

Edwards Lifesciences' deal with JenaValve would limit device access, US FTC says MLex

JenaValve TAVR wins FDA breakthrough device designation - MassDevice

JenaValve TAVR wins FDA breakthrough device designation MassDevice

TAVR developer JenaValve nets $50M from Bain Capital Life Sciences - Fierce Biotech

TAVR developer JenaValve nets $50M from Bain Capital Life Sciences Fierce Biotech

JenaValve Announces First Implantations Of Transapical TAVI System In Canada - Diagnostic and Interventional Cardiology

JenaValve Announces First Implantations Of Transapical TAVI System In Canada Diagnostic and Interventional Cardiology

JenaValve Raises $62.5 Million In Venture Funding - Diagnostic and Interventional Cardiology

JenaValve Raises $62.5 Million In Venture Funding Diagnostic and Interventional Cardiology

JenaValve TAVI System Receives Extended CE Mark Approval - Diagnostic and Interventional Cardiology

JenaValve TAVI System Receives Extended CE Mark Approval Diagnostic and Interventional Cardiology

Top Jenavalve Technology, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant